Study: Benefits of Cannabinoids Extend Beyond Spasticity in Those With Multiple Sclerosis – TheJointBlog

  • may extend beyond spasticity, improving spasticity-related symptoms even in non-NRS responder patients.
  • The approval of 9–tetrahydocannabinol (THC)+cannabidiol (CBD) oromucosal spray (Sativex) in Italy as an add-on medication for the management of moderate to severe spasticity in multiple sclerosis (MS) has provided a new opportunity for MS patients with drug-resistant spasticity, states the study.
  • We aimed to investigate the improvement of MS spasticity-related symptoms in a large cohort of patients with moderate to severe spasticity in daily clinical practice.

Read full article: